Национальная контактная точка "Здравоохранение"

Comment le patient cialis pharmacie cialis est-il informé?

Innovative Medicines Initiative launches new Calls for proposals

The Innovative Medicines Initiative has now launched IMI2 – Call 13.

§ Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches

§ Genome-environment interactions in inflammatory skin disease

§ The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

§ Mitochondrial dysfunction in neurodegeneration

§ Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative

§ A sustainable European induced pluripotent stem cell platform

§ Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice

§ Human tumour microenvironment immunoprofiling

§ ConcePTION – Continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now

§ Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system

§ Translational safety biomarker pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease

§ Pilot programme on a clinical compound bank for repurposing – this programme contains four topics on cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; and rare/orphan diseases

Deadline for submitting short proposals: 28 February 2018

All topic texts, Call documentation and details of how to apply can be found on the IMI website – www.imi.europa.eu

Registration is open for the webinars on IMI2 – Call 13, which run until 15 December.

Наши партнеры